Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

Updates on Amendment and Notification Applications for Site Licences

Nov 3, 2025

Health Canada, under Bulletin No. 8, has provided updates to help streamline the site licence amendment and notification process for NHPs, improving predictability and speeding up license decisions. Key updates: Separate submissions: Amendment applications must be...

Health Canada Opens Consultation on Draft Guidance for Drug and Natural Health Product Summary Reports

Nov 3, 2025

Health Canada has launched a 60-day public consultation on its revised “Draft guidance on preparing and submitting summary reports for marketed drugs and natural health products.” The consultation period opened on October 24, 2025, and will close on December 23, 2025....

Health Canada Boosts NHP Transparency: GMP Inspection Results Going Public!

Nov 3, 2025

Health Canada is stepping up transparency by making NHP GMP inspection results publicly available on the Drug and Health Product Inspection Database (DHPID) as of October 29, 2025. This is a significant move that aligns NHP oversight with other regulated health...

FDA Launches Public Dashboard for Real-Time Cosmetic Adverse Event Data

Oct 28, 2025

In a significant move towards increased transparency under the Modernization of Cosmetics Regulation Act (MoCRA), the U.S. Food and Drug Administration (FDA) has launched the FDA Adverse Event Reporting System (FAERS) Public Dashboard for Cosmetic Products. This new,...

Reminder: California EPR Reporting Deadline is November 15

Oct 28, 2025

This is an important reminder for businesses subject to California’s Extended Producer Responsibility (EPR) law for packaging. The Circular Action Alliance (CAA), the Producer Responsibility Organization managing the program, is urging all single-use packaging...

California introduces the “C.U.R.L. Act” to ban certain Hair Relaxers Ingredients

Oct 28, 2025

The California Legislature has passed a new bill, SB 236, also known as the Combating Unsafe Relaxers (C.U.R.L) Act. This bill prohibits any person from manufacturing, distributing, selling, or offering for sale in California any hair relaxer product that contains a...

California Governor Vetoes Bill to Ban Plastic Glitter (AB 823)

Oct 28, 2025

In another significant move to regulate cosmetic ingredients, the California Legislature had passed Assembly Bill (AB) 823. The bill was ready for Governor’s signature, but there has been a major reversal in the status of California's Assembly Bill (AB) 823. Governor...

California Finalizes Prop 65 Safe Harbor Levels for Titanium Dioxide

Oct 28, 2025

California’s Office of Environmental Health Hazard Assessment (OEHHA) has adopted a new regulation establishing No Significant Risk Levels (NSRLs) for titanium dioxide under Proposition 65. This action specifically targets airborne, unbound particles of respirable...

New Sunscreen Filter, Bemotrizinol, on track for FDA Approval

Oct 28, 2025

A new sunscreen ingredient, bemotrizinol, is currently under review by the U.S. Food and Drug Administration (FDA) and could be the first new UV filter to be approved in the United States in decades. The European skincare company DSM-Firmenich has submitted a Time and...

FDA encourages Alternatives to Animal Testing for Sunscreens

Oct 28, 2025

The U.S. Food and Drug Administration (FDA) is encouraging the development of new, reliable alternatives to animal testing for sunscreen products. This comes as the agency continues its work on a proposed order, first issued in September 2021, to update the monograph...

« Older Entries

“Focal Point Research has consistently and professionally looked after regulatory and quality issues of our brand for years. Through a courteous and knowledgeable team, they have managed to navigate us through an ever changing regulatory landscape while maintaining our interests, and allowed us to correctly distribute and sell within Canada.”

“I have truly enjoyed working with you over the last 8 years! You and your team have been an amazing resource for me. I have always been impressed by the knowledge and professionalism of everyone at Focal Point, which is a true testament to your leadership.”

Connect With Us

The Focal Point Research team is ready to help with all of your scientific and regulatory needs. Our team has the experience and expertise you need to see your product to market and we are eager to help you.

181 Lakeshore Road E. Mississauga, ON

1 (905) 271 2709

mail@focalpointresearch.net

Delsie Braganza

Jennifer Porter, BA Psychology, MBA – President & CEO

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

Connect With Us